Business Context and Reporting Period
Company: Metavia Inc. (MTVA)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Metavia is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. Its primary programs are Vanoglipel (DA-1241) for metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 Diabetes, and DA-1726 for obesity. The company operates as a single reportable segment and has no product revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,377) | $(5,652) | $(11,043) | $(22,419) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.55) | $(0.63) | $(3.24) |
| Operating Expenses | $3,475 | $6,259 | $11,662 | $23,224 |
| Cash and Cash Equivalents (End of Period) | $14,277 | $21,669 | $14,277 | $21,669 |
| Net Cash Used in Operating Activities | N/A | N/A | $(10,841) | $(19,241) |
| Accumulated Deficit | $(146,900) | $(130,684) | $(146,900) | $(130,684) |
Liquidity: As of September 30, 2025, the company held $14.3 million in cash. Total current liabilities were $8.4 million, including a $3.3 million related party payable to Dong-A ST Co., Ltd.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 44.5% in Q3 2025 compared to Q3 2024 ($3.5M vs $6.3M) and by 49.8% for the nine-month period ($11.7M vs $23.2M). This was driven primarily by reduced R&D spending on Vanoglipel and DA-1726 clinical trials.
- R&D Spend: R&D expenses dropped significantly, with direct costs for Vanoglipel decreasing by $2.4M in Q3 and $7.6M for the nine months compared to the prior year.
- Capital Raise: In May 2025, the company completed a private placement with related parties (Dong-A ST and affiliate), raising net proceeds of $9.1 million through the issuance of common stock and pre-funded warrants.
- Warrant Liability: The fair value of warrant liabilities decreased from $361,000 at year-end 2024 to $167,000 at September 30, 2025, resulting in a non-cash gain of $194,000 for the nine months ended September 30, 2025.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that conditions raise "substantial doubt" about the company's ability to continue as a going concern within one year. Management expects to continue incurring net losses and negative cash flows due to ongoing clinical trials.
- Capital Needs: The company plans to fund operations through equity offerings, debt financing, or warrant exercises. Failure to secure additional capital could force the company to slow or stop clinical trials.
- Clinical Progress:
- Vanoglipel (DA-1241): Finalizing the Clinical Study Report for the Phase 2a trial in MASH; working to schedule an end-of-Phase 2 meeting with the FDA.
- DA-1726: Conducting Phase 1 trials. In July 2025, the first patient was dosed in a 48 mg multiple ascending dose (MAD) cohort. Top-line data for this cohort is expected in Q4 2025.
- New Agreements: In August 2025, the company announced a research collaboration with Syntekabio, Inc. to identify disease targets for Vanoglipel. In November 2025, an "At The Market" offering agreement was entered into to sell up to $2.3 million of common stock.
- Risks: Key risks include the inability to raise capital, regulatory approval uncertainties, and the potential for significant dilution to existing shareholders.
Investor Verification Checklist
- Cash Runway: Verify if the $14.3 million cash balance is sufficient to fund operations through the expected completion of current clinical trials without immediate additional financing.
- Related Party Transactions: Review the $3.3 million payable to Dong-A ST and the terms of the Shared Services Agreement to understand payment obligations and potential conflicts of interest.
- Warrant Expirations: Monitor the status of outstanding warrants, specifically the Series A warrants which expired unexercised in June 2025, and the Series B warrants which have a cashless exercise provision.
- Clinical Milestones: Confirm the timeline for the release of top-line data for the DA-1726 48 mg MAD cohort (expected Q4 2025) and the FDA end-of-Phase 2 meeting for Vanoglipel.
- Dilution Impact: Assess the potential dilution from the new "At The Market" offering agreement and any future equity raises required to address the going concern uncertainty.